TORONTO--(BUSINESS WIRE)--Researchers from the Johns Hopkins University School of Medicine have entered into an agreement with Axela Inc. to use dotLab® technology in a clinical trial that evaluates circulating cardiac Troponin complexes (cTn) directly in patient samples. Dr. Jennifer Van Eyk, Director of the Johns Hopkins NHLBI Proteomics Center (JHNBPC) in Baltimore, U.S.A., is the lead researcher for this trial. The trial will look at the prognostic value of Troponin complexes as well as post translational modifications to cardiac Troponin I (cTnI) in patients with Acute Myocardial Infarction (AMI).
